SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently trending due to unconfirmed but persistent market speculation regarding a potential multibillion-dollar acquisition by a larger biopharmaceutical player. Investors are actively debating the company's valuation, comparing recent pipeline advancements and commercial performance to previous sector buyouts while awaiting further news to validate the significant uptick in trading volume and price action.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin, triggering intense debate between traders hoping for rapid gains and community members warning of a potential rug pull due to extreme holder concentration. While some enthusiasts highlight its volatile price movements and aggressive social media promotion, many skeptics view the asset as a classic pump-and-dump scheme with no inherent utility.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund, trading as VCX, has experienced significant volatility and massive price premiums over its net asset value since its recent IPO, with investors heavily focused on its portfolio of private AI giants like Anthropic and SpaceX. Much of the community conversation is centered on the six-month lockup period affecting early shareholders, fueling heated debates between those holding for long-term growth and others bracing for a potential price correction.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is generating significant buzz as investors weigh upcoming earnings reports against expectations for a major NASA Lunar Terrain Vehicle (LTV) contract award. The community remains deeply divided, with bulls pointing to strong forward revenue guidance and long-term space infrastructure growth, while bears emphasize execution risks and the volatility associated with contract timing.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is currently generating intense debate among retail traders, with bulls pointing to edge computing and AI exposure as catalysts for a massive run, while bears warn of extreme overvaluation and heavy insider selling. The community is sharply divided between those who believe the stock is undergoing a legitimate short squeeze and those convinced it is a manipulated pump-and-dump scheme.

CBIZ, Inc. is a professional services advisor to middle market businesses and organizations nationwide. It offers its services in accounting, tax, advisory, benefits, insurance, and technology. The firm delivers forward-thinking insights and actionable solutions to help clients anticipate what's next and discover new ways to accelerate growth. It operates through the following segments: Financial Services, Benefits and Insurance Services and National Practices. The Financial Services segment offers accounting, tax, government health care consulting, financial advisory, valuation, and risk advisory services. The Benefits and Insurance Services segment includes group health benefits consulting, property and casualty brokerage, retirement plan services, and payroll. The National Practices segment deals with managed networking and hardware, and healthcare consulting. The company was founded by Michael G. DeGroote Sr. in 1987 and is headquartered in Independence, OH.

Cbiz Inc

Investors are actively debating the long-term outlook for CBIZ as the firm navigates integration challenges following major mergers. Discussions highlight concerns over recent financial performance and debt levels, while the community remains divided between those viewing the current valuation as an oversold opportunity and others wary of ongoing corporate headwinds.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investor interest surges following the company's recent Medicare coverage approval for its NeXT Personal MRD test in breast cancer, a major milestone that removes a key barrier to commercial scaling. Community sentiment is overwhelmingly bullish, with active discussions focusing on the companys potential as a takeover target, its deep integration with Tempus AI, and the expected rapid revenue expansion as additional oncology indications secure regulatory reimbursement.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Investors are actively discussing 4CHAN as a "cultural index" or "source code" for the broader meme coin market, citing its status as the original birthplace of internet memes as a key value proposition. The community is focused on the token's high liquidity and scarcity model, often comparing its potential to Bitcoin or major memecoins while viewing current market volatility as a prime accumulation window for long-term holders.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened volatility and intense social media chatter as investors brace for a critical upcoming earnings report and potential acquisition developments. Community sentiment remains deeply polarized between long-term holders anticipating a business transformation and skeptical traders concerned about recent price stagnation and transparency.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc

Apollo Global Management is currently in focus as investors analyze the firm's strategic positioning within the private credit sector and its potential for long-term growth driven by robust asset management inflows. The community is actively discussing the firm's ability to maintain performance amidst evolving macro conditions, while keeping a close watch on leadership insights regarding market stability and capital deployment strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Bicycle Therapeutics (NASDAQ:BCYC) Raised to Hold at Wall Street Zen

Wall Street Zen raised shares of Bicycle Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $36.00 at Oppenheimer

Oppenheimer decreased their target price on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an "outperform" rating for the company in a research note on Wednesday...

Bicycle Therapeutics (NASDAQ:BCYC) Given New $7.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada reduced their target price on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a "sector perform" rating for the company in a report on Wednesday...

Bicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $8.00 by Analysts at Citizens Jmp

Citizens Jmp reduced their price target on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Wednesday...

Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $15.00 at Needham & Company LLC

Needham & Company LLC dropped their price target on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a "buy" rating on the stock in a research report on Wednesday...

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Bicycle Therapeutics (NASDAQ:BCYC) Issues Quarterly Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.71...

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven research firms that are currently covering the...

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Current Price	$4.34
Prev Close	$4.35
Open	$4.50
Dividend Yield	0.00%
50-Day Moving Average	$5.77
Beta	1.20
Avg. Volume	467,320.97
PE Ratio	-1.37

52-Week High	$9.69
52-Week Low	$4.25
Market Capitalization	$216.7M
EPS (Annual)	-$3.17
Price to Book	0.49
Revenue Per Employee	$252,623.69

BCYC
Bicycle Therapeutics Plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCYC News

BCYCBicycle Therapeutics Plc - ADR